Cigna Group (NYSE:CI – Get Free Report) had its price target lifted by research analysts at Barclays from $304.00 to $310.00 in a report issued on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the health services provider’s stock. Barclays‘s target price would indicate a potential upside of 7.80% from the company’s current price.
CI has been the topic of a number of other research reports. Jefferies Financial Group lowered their price objective on shares of Cigna Group from $333.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. UBS Group boosted their target price on shares of Cigna Group from $375.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Sanford C. Bernstein lifted their price objective on Cigna Group from $371.00 to $381.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Robert W. Baird set a $337.00 target price on Cigna Group in a research report on Friday, May 1st. Finally, The Goldman Sachs Group upped their target price on shares of Cigna Group from $335.00 to $340.00 and gave the company a “buy” rating in a report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $339.10.
Get Our Latest Stock Report on Cigna Group
Cigna Group Trading Down 3.0%
Cigna Group (NYSE:CI – Get Free Report) last issued its earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share for the quarter, topping analysts’ consensus estimates of $7.60 by $0.18. The business had revenue of $70.04 billion during the quarter, compared to analyst estimates of $70.14 billion. Cigna Group had a return on equity of 19.75% and a net margin of 2.26%.Cigna Group’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $7.20 EPS. Cigna Group has set its FY 2026 guidance at 30.450- EPS. On average, sell-side analysts predict that Cigna Group will post 30.39 EPS for the current year.
Insider Activity at Cigna Group
In other Cigna Group news, CAO Jamie G. Kates sold 899 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $298.61, for a total transaction of $268,450.39. Following the sale, the chief accounting officer owned 2,368 shares in the company, valued at approximately $707,108.48. The trade was a 27.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David Cordani sold 201,878 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $292.82, for a total value of $59,113,915.96. Following the completion of the transaction, the chief executive officer directly owned 34,337 shares of the company’s stock, valued at approximately $10,054,560.34. This trade represents a 85.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.60% of the company’s stock.
Institutional Trading of Cigna Group
A number of institutional investors have recently made changes to their positions in the company. Assetmark Inc. boosted its stake in Cigna Group by 10.0% during the first quarter. Assetmark Inc. now owns 65,662 shares of the health services provider’s stock worth $17,515,000 after buying an additional 5,963 shares during the last quarter. OFI Invest Asset Management increased its holdings in Cigna Group by 8,357.8% in the 4th quarter. OFI Invest Asset Management now owns 33,070 shares of the health services provider’s stock valued at $9,102,000 after purchasing an additional 32,679 shares during the last quarter. Banque Pictet & Cie SA raised its holdings in shares of Cigna Group by 40.0% in the 4th quarter. Banque Pictet & Cie SA now owns 25,216 shares of the health services provider’s stock valued at $6,940,000 after buying an additional 7,204 shares during the period. Victory Capital Management Inc. raised its stake in shares of Cigna Group by 41.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,348,713 shares of the health services provider’s stock valued at $371,206,000 after acquiring an additional 392,978 shares in the last quarter. Finally, CWM LLC raised its position in Cigna Group by 12.7% in the 4th quarter. CWM LLC now owns 84,803 shares of the health services provider’s stock valued at $23,340,000 after purchasing an additional 9,566 shares in the last quarter. 86.99% of the stock is owned by institutional investors and hedge funds.
Key Cigna Group News
Here are the key news stories impacting Cigna Group this week:
- Positive Sentiment: Cigna reported adjusted earnings of $7.78 per share, ahead of the roughly $7.60 consensus estimate and up from $7.20 a year earlier. Total revenue increased 7% year over year to approximately $71.7 billion, supported by growth across its healthcare and pharmacy-benefit businesses. The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook
- Positive Sentiment: Management raised its 2026 adjusted income-from-operations outlook to at least $30.45 per share, modestly above the approximately $30.40 analyst consensus. Cigna Healthcare revenue rose 9%, while Evernorth Health Services revenue increased 6%, signaling broad-based operating momentum. Cigna raises annual profit forecast on strength in health services unit
- Neutral Sentiment: The company generated nearly $1.7 billion in quarterly net income, or $6.29 per share, and repurchased about $250 million of stock year to date. However, elevated medical and pharmacy costs remain an industry-wide profitability risk. As New CEO Takes Charge, Cigna Reports $1.7 Billion Quarterly Profit
- Negative Sentiment: Cigna indicated that growth in prescriptions for popular GLP-1 weight-loss drugs may slow. Investors may view this as a potential constraint on future pharmacy-benefit growth, particularly as higher pharmacy costs pressure margins. Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions
Cigna Group Company Profile
Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.
In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.
Further Reading
- Five stocks we like better than Cigna Group
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
Receive News & Ratings for Cigna Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Group and related companies with MarketBeat.com's FREE daily email newsletter.
